ALGORITHM OF TREATMENT AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE


Cite item

Full Text

Abstract

In recent years, on national and international levels more and more attention is paid to the problem of chronic obstructive pulmonary disease (COPD). This is primarily due to growth not only morbidity but also mortality in patients with this disease. The most important factor for development of disease is significant morphofunctional changes in the lungs, that primarily caused by tobacco smoking. The pathological process in patients with COPD is represented by inflammation in the wall of the bronchial tree, lung parenchyma and pulmonary vessels. Inflammation in COPD is not well curable by anti-inflammatory drugs as in bronchial asthma. In addition, this disease is characterized by systemic effects, and the approach to their correction is different from that in other diseases of the lungs.

References

  1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Доклад рабочей группы GOLD (Global Initiative for Chronic Obstructive Lung Disease) - пересмотр 2006 / Под редакцией А.Г. Чучалина.
  2. Global Initiative for Chronic Obstructive Lung Disease. Revised 2006.
  3. Респираторная Медицина. Руководство / Под редакцией А.Г. Чучалина. М., 2007. Т. 1. С. 626.
  4. Anthonisen NR, Connett JE, Murray RP, et al. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-79.
  5. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269.
  6. Barnes PJ, Adcock IM, Ito K. Histone diacetylation and deacetylation importance in inflammatory lung diseases. Eur Respir J 2005;25(3):552-63.
  7. Domagala-Kulawik J, Hoser G, Dabrowska M, et al. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med 2006;10:20.
  8. Moratti R, Quaglini S, Alesina R, et al. Increased serum inflammatory markers as predictors of airway obstruction. J Asthma 2006;43(8):593-6.
  9. Чучалин А.Г. Система оксиданты и антиоксидвнты и пути коррекции // Пульмунология 2004. № 4. С. 111-15.
  10. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ // Атмосфера Пульмонология и аллергология 2000. № 5. С. 27-31.
  11. Rytila P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006;28(7):69.
  12. Yigla M, Berkovich Y, Nagler RM. Oxidative stress indices in COPD-Broncho-alveolar lavage and salivary analysis. Arch Oral Biol 2007;52(1):36-43.
  13. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J Suppl 2003;46:2-4.
  14. The association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis / W.Q.Gan, S. F.Man, A.Senthilselvan, D. D.Sin // Thorax. 2004. Vol. 59. P. 574-580.
  15. Kluchova Z, Petrasova D, Joppa P, et al. The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol Res 2007;56(1):51-6.
  16. Vestbo J, TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004;24:206-10.
  17. Sin DD, Anthonisen NR, Soriano JВ, et al. Role of comorbidities. Eur Respir J 2006;28(6):1245-57.
  18. Сахарова Г.М. Воздействие курения табака на организм // Качество жизни. Медицина 2004. № 1. C. 18-22.
  19. Feenstra TL, Genugten ML, Hoogenveen RT, et al The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001;164:590-96.
  20. Белевский А.С. // Consilium Medicum 2006. Т. 8. № 10.
  21. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8.
  22. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3:1-11.
  23. Авдеев С.Н. Возможность уменьшения числа обострений у больных ХОБЛ при длительном приеме N-ацетилцистеина // Пульмонология 2007. № 2. С. 89-97.
  24. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obctructive airways disease in the emergency room. Am J Med 1987;82:59-64.
  25. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1:303-12.
  26. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
  27. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008;359:1543-54
  28. Kottakis J, Wood R, Le Gros V, et al. Clinical efficacy with formoterol in the absence of a response to salmeterol: A review. Int J Clin Pract 2001;55:476-9.
  29. Сazzola M, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114(2):411-5.
  30. Briggs DD Jr, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18:397-404.
  31. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-17.
  32. Surge P, Calverley P, Jones P, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit Med J 2000;320:1297-303.
  33. Sin D, Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-84.
  34. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003;21:260-66.
  35. Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med 2003;168:1-2
  36. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003;361:449-56.
  37. Calverley PMA, Anderson JA, Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89.
  38. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-43.
  39. Soriano JВ, Vestbo J, Pride NB, et al. Survival in COPD patients after use of salmeterol and/or fluticasone propionate in general practice. Eur Respir J 2002;20:819-25.
  40. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
  41. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Pract 2009;63:1136-49.
  42. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med 2009;180:741-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies